Sign in
Enrolling by invitationNo phase

Tests NVP-NK4146 supplement in people with mild memory and thinking problems from Alzheimer's

Tests NVP-NK4146 supplement against placebo in adults over 60 with Alzheimer's-related mild cognitive impairment.

Key facts

Who runs it
NVP Healthcare
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Status
Enrolling by invitation
People taking part
60 people, planned
Started
20 Jan 2026
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NVP-NK4146
  • NVP-NK4146 Placebo
Record updated
1 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 60 or older with mild cognitive impairment (MCI) due to Alzheimer's disease and a positive amyloid PET scan.

Age
60 years or older
Sex
Men and women can join.
Disease stage
Mild cognitive impairment (MCI) due to Alzheimer's disease, meeting the NIA-AA core clinical criteria. People with dementia cannot join.
Biomarker or test result
A positive amyloid PET scan reading.

Main reasons for not taking part

  • Diagnosed with dementia (DSM-5 or ICD-10 criteria)
  • Currently receiving treatment for a malignant tumor (some exceptions at the investigator's discretion)
  • Cannot read or has no education at all

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Male and female adults aged 60 or older
  • Subject who meet the National Institute of Aging and Alzheimer's Associations (NIA-AA) core clinical criteria for MCI and have positive readings from amyloid PET
  • Subject who can read and understand the Informed Consent Form and legends and who voluntarily decided to participate in current clinical trial and have signed the Informed Consent Form

Who cannot take part

  • Subject currently receiving treatment for malignant tumors (except those who have fully recovered from cancer for more than 5 years or those with basal cell carcinoma, squamous cell carcinoma, or prostate cancer may participate at the investigator's discretion)
  • Subject diagnosed with dementia according to the criteria of DSM-5 or ICD-10
  • Subject who are illiterate and/or without any education
  • Any other factors deemed by the investigator to be likely to ineligible for the study

Where in South Korea

  • The Catholic University of Korea Yeouido St. Mary's HospitalSeoul, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo

The 2 groups in the trial

  • Active GroupTreatment being tested

    NVP-NK4146

    Treatment: NVP-NK4146

  • Placebo GroupPlacebo, for comparison

    NVP-NK4146 Placebo

    Treatment: NVP-NK4146 Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
36-week, Single-center, Randomized, Double-blind, Parallel-design, Placebo-controlled Trial to Determine the Safety and Efficacy of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Plain-language title
Tests NVP-NK4146 supplement in people with mild memory and thinking problems from Alzheimer'sGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
1 September 2026